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a b s t r a c t
Aim: Quantitative evaluation of the effect caused by vaginal administration of gelatin capsules loaded
with starch pellets and lyophilized powder, respectively, on vaginal pH and microflora.
Method: Administration of gelatin capsules loaded with fast-disintegrating starch pellets (group P) or
lyophilized lactose/skimmed milk (group L) was compared to no intervention (group C) in a 3-way ran-
domized, double-blinded, parallel study with 18 volunteers. Follow-up visits were at day 6 (immediately
after administration), day 14 (pill stop), day 22 (after withdrawal bleeding) and day 35 (midcycle). Vag-
inal pH was measured and swabs were taken for Gram staining and culture to assess the presence of
hydrogen peroxide-producing lactobacilli. Colposcopy was performed to assess the occurrence of adverse
effects on the vaginal and ectocervical mucosa.
Results: No severe adverse events occurred. For all women, vaginal pH and Gram stain were normal from
screening until pill stop. Although immediately after withdrawal bleeding, 8 out of 18 women had an ele-
vated pH, a disturbed microflora or lacked hydrogen peroxide-producing lactobacilli, all women had
hydrogen peroxide-producing lactobacilli and a normal vaginal pH at midcycle, and all but two had a nor-
mal Gram stain.
Conclusion: No major differences could be observed between the groups, whereby all changes in pH and
microflora could be ascribed to withdrawal bleeding, indicating that gelatin capsules, starch pellets and
lyophilized powder are acceptable carrier materials for the vaginal delivery of probiotic strains.
! 2009 Elsevier B.V. All rights reserved.
1. Introduction
Bacterial vaginosis (BV), a condition whereby hydrogen perox-
ide (H2O2)-producing lactobacilli are overgrown by anaerobic bac-
teria, is the most common etiology of vaginal symptoms prompting
women to seek medical care and confers an increased risk of pre-
term delivery in pregnant women [1,2]. While currently available
antibiotic treatments establish short-term symptomatic improve-
ment but do not prevent high rates of recurrence of BV; exogenous
supplementation of vaginal lactobacilli could restore the vaginal
microflora [3,4].
An optimal formulation for vaginal delivery of probiotic strains
should (1) have a long retention time to maximize release of the
probiotic strain, (2) have a proper spreading over the vaginal vault
to establish colonization of the probiotic strain on different sites of
the vaginal tract, (3) not cause harm to the normal vaginal micro-
flora and mucosa, (4) be easy to administer and (5) not cause dis-
comfort to the patient.
Different types of formulations for delivery of vaginal probiotics
are commercially available, but the main group of vaginal probiotic
delivery forms is lyophilized powders compacted into tablets and
lyophilized powders with a gelatin-based encapsulation. Also tam-
pons impregnated with lactobacilli are commercially available.
Probiotic strains are always used in combination with other
synergistically acting and stabilizing ingredients. The probiotic for-
mula can be improved by using the right bioadhesive (e.g. gelatin
or hydroxyl propyl methyl cellulose) and carrier (e.g. starch), by
0939-6411/$ - see front matter ! 2009 Elsevier B.V. All rights reserved.
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adding energy sources (e.g. glucose), prebiotics (e.g. lactitol), vita-
mins (e.g. ascorbic acid), freeze dry protectants and preservatives
(e.g. lactose), tablet stabilizers (e.g. magnesium stearate), essential
fatty acids (e.g. alpha linoleic acid) and trace elements (e.g. sele-
nium) [5]. Several other classes of synergistically acting com-
pounds have been used.
In a previous study, we found starch-based pellets to be a prom-
ising new vaginal delivery form, considering the more efficient dis-
tribution and longer retention time in the vagina compared to
lyophilized powder [6]. It is expected that this new delivery form
will enhance the colonization potential of vaginal probiotic strains,
leading to a healthier vaginal microflora. The main purpose of this
prospective study was to assess whether addition of the carrier
material itself does not disrupt the natural protective microflora
in the vagina. Both starch-based pellets and lyophilized lactose/
skimmedmilk (lyophilized powder) were tested as carriers for vag-
inal probiotic bacteria. A non-treated control group was included
to follow the natural evolution of pH and microflora during the
menstrual cycle.
2. Materials and methods
2.1. Subjects
We recruited premenopausal non-pregnant women aged
18–50 years with a presumed healthy vaginal microflora and on
monophasic pills. Exclusion criteria were history of vaginal surgery
and hysterectomy, diagnosed pubis dysfunction, reoccurring vagi-
nal infections (<1 year), active vaginal infections, vulval or vaginal
active dermatological aberrations, anamneses of breakthrough
bleeding while using oral contraceptives, use of hormone- or cop-
per-releasing IUDs, use of vaginal anticonceptives, i.e. NuvaRing,
sexual contact of any kind 48 h before the screening, use of local
or systemic antibiotics, including antimycotics and antiprotozoals,
from 3 weeks before the start of the study and for the course of the
study. Testing for Chlamydia trachomatis by DNA amplification was
done at the baseline visit (Abbott RealTime CT, Abbott Laborato-
ries, Illinois, US) on an endocervical swab specimen. Subjects
who tested positive for C. trachomatis were excluded.
This study was approved by the research ethics committee (EC
UZG 2008/114) of Ghent University Hospital, Belgium.
2.2. Study design
After oral and written informed consent, 18 volunteers were
randomized, in a double-blinded fashion, into three different
groups of six subjects. The first group had to vaginally administer
a gelatin capsule loaded with disintegrating starch pellets, without
probiotics, for 5 days. The second group had to vaginally adminis-
ter a gelatin capsule loaded with lyophilized lactose/skimmed milk
(ratio 1/2) powder, without probiotics, for 5 days. The third group
had no intervention. All women were on oral contraception (OC)
confined to monophasic combination pills and were instructed to
continue OC use until day 14 and then to reinitiate OC use on
day 22.
The three groups returned for a gynecological control visit on
four separate, well-defined days, i.e. on day 6, the first day after
the last vaginal administration, on day 14 at pill stop, at the end
of the withdrawal bleeding on day 22, and on day 35, at the mid-
cycle of the next pill cycle. At each follow-up visit, a standard gyne-
cological examination including colposcopy was performed.
Evaluation of the vaginal and cervical mucosa through colposcopy
was performed according to the CONRAD/WHO guidelines for the
evaluation of vaginal products. On each visit, a vaginal swab (Es-
wab, Copan, Brescia, Italy) was taken and pH was measured with
a pH test strip (Macherey–Nagel, Düren, Germany). Subjects were
instructed to record in a diary any symptoms or complaints occur-
ring throughout the study period.
2.3. Vaginal formulations
The multi-particulate starch-based pellets were produced by
extrusion/spheronisation. Dry mixing was performed in a Turbula"
mixer (model T 2A, W.A. Bachofen, Basel, Switzerland) for 15 min.
The powder mixture was granulated with demineralised water for
10 min using a planetary mixer (Kenwood Chief, Hampshire, UK)
with a K-shaped mixing arm. Water was added during the first
30 s of the wet massing phase. To ensure uniform water distribu-
tion, the material adhering to the mixing bowl was regularly re-
moved. The wet mass was extruded at an extrusion speed of
50 rpm using a single screw extruder (Dome extruder lab model
DG-L1, Fuji Paudal, Tokyo, Japan) equipped with a dome-shaped
extrusion screen with 0.4 mm perforations. The extrudates were
spheronised in a spheroniser having a friction plate with cross-
hatched geometry (Caleva Model 15, Caleva, Sturminster Newton,
Dorset, UK). Spheronisation time was 3 min and spheronisation
speed was 1000 rpm. The pellets were dried overnight in an oven
(Memmert, Schwabach, Germany) at 40 #C.
Gelatin capsules (size 00, Nova, Belgica T.O.P. nv, Turnhout, Bel-
gium) were administered via a commercially available applicator
(Infemin applicator, Pierre Fabre santé Benelux, Brussels, Belgium)
and were filled with either fast-disintegrating starch pellets (size
500–710 lm, 753.7 mg SD 12.6), consisting of 84.9% Uni-Pure EX
starch (National starch Chemical Company, New Jersey, United
States), 4.9% Methocel E 15 (Colorcon, Dartford, Great Britain)
and 10.2% sorbitol (Cerestar, Mechelen, Belgium), or with lyophi-
lized powder (456.8 mg SD 5.8) consisting of 33.3% lactose (a-
Pharma, Braine L’Alleud, Belgium) and 66.6% skimmed milk (Difco,
Becton Dickinson, Erembodegem, Belgium). Both kinds of capsules
were visually indistinguishable.
2.4. Grading of Gram-stained vaginal smears
The Gram-stained vaginal smears were scored by three inde-
pendent assessors (GC, RV and GL) according to the criteria previ-
ously described [7]. Briefly, Gram-stained vaginal smears were
categorized as grade I (normal) when only Lactobacillus cell types
were present, as grade II (intermediate) when both Lactobacillus
and bacterial vaginosis-associated cell types were present, as grade
III (bacterial vaginosis) when bacterial vaginosis-associated cell
types were abundant in the absence of lactobacilli, as grade IV
when only Gram positive cocci were observed, as grade I-like when
Gram positive rods either quite small and short or otherwise irreg-
ularly shaped with curved edges were predominant [7], and as
grade 0 when no bacterial cells were present.
Grade I specimens were further subdivided into grade Ia spec-
imens when only Lactobacillus crispatus cell types (plump, mostly
short rods) were present, into grade Ib when only other Lactoba-
cillus cell types were present (smaller or more elongated and less
stained than in Ia smears) and into grade Iab when both L. crisp-
atus and other lactobacilli were present. An additional Gram stain
category, grade I-Polymorphonuclear neutrophils (I-PMN), was
assigned to ‘idiopathic purulent grade I’ smears, i.e. smears show-
ing heavy leukorrhea with PMN (i.e. more than 50 PMN per high
power field (hpf)) in the presence of normal numbers of Lactoba-
cillus spp., but in the absence of pathogens such as Candida spp.
[8]. The number of PMN and of bare nuclei, resulting from cytol-
ysis, was scored as low (less than 10 per hpf), intermediate
(between 10 and 50 per hpf) or high (more than 50 per hpf)
[9,10].
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For the purpose of this study, grade I or Lactobacillus-dominated
vaginal microflora is designated as ‘normal vaginal microflora’ and
all other grades as ‘abnormal vaginal microflora’.
2.5. Hydrogen peroxide production
The presence of vaginal microorganisms producing hydrogen
peroxide was assessed by direct inoculation of 75 ll of ESwab
medium on TMBplus agar plates [11]. After a 2 day incubation per-
iod at 37 #C in an anaerobic chamber (BugBox, LedTechno, Heus-
den-Zolder, Belgium), the plates were exposed to oxygen for
1.5 h and photographed. Each plate was given a score according
to the intensity of the color: score 0 when no H2O2 was produced,
score 1 for weak H2O2 production, score 2 for strong H2O2 produc-
tion and score 3 for very strong H2O2 production (Fig. 1).
3. Results
Eighteen women on monophasic oral contraceptives (OC) were
enrolled, whereby all continued taking OCs after the screening vis-
it, but stopped after day 14 of enrollment to evoke a withdrawal
bleeding. All women were randomized in three groups, i.e. group
P, administering capsules filled with starch-based pellets, group
L, administering capsules filled with lyophilized powder or the
control group (group C), not administering capsules. All women
completed a diary, recording symptoms that occurred during the
6-week study period. All women completed the study and adhered
to the study protocol.
3.1. Adverse events and adverse effects
No adverse effects on the vaginal and ectocervical mucosa were
observed throughout the study period, nor were any serious ad-
verse events (SAE) reported by the study participants (Table 1).
In the control group, three women did not report any adverse
events (AEs), while three women reported one, two and four AEs,
respectively (median of 0.5 AEs per patient). In group L, five out
of six study participants reported at least one AE, with a median
of 1.5 AEs. Finally, in group P, all patients reported at least one
AE, with a median of 2.5 AEs per patient. There was no significant
difference in the occurrence of AEs between groups (Kruskal–Wal-
lis p = 0.215).
3.2. Vaginal pH
At screening, the pH was lower than 4.7 and thus normal for all
but two volunteers who presented with an elevated pH due to the
presence of menstrual blood (Fig. 2). Immediately after administra-
tion, at day 6, the vaginal pH was normal for all groups, except for
one woman in group P with elevated pH (5.0), who also had a
Gram-stained smear with few bacteria at screening and through-
out the study period. While at day 14, all pH values were normal,
on day 22, i.e. after withdrawal bleeding, mean pH increased in
all groups. Respectively, three, two and two volunteers in group
C, group P and group L had a pH higher than 4.7 (Fig. 2). At day
35, all subjects, except one with residual blood loss, had a vaginal
pH lower than or equal to 4.7.
3.3. Effect on microflora as assessed by Gram stain
At screening, all subjects had a normal vaginal microflora (i.e.
grade Ia, Ib or Iab) except for one in group P who had a smear al-
most devoid of bacteria and another one in group L for whom
the smear showed heavy leukorrhea with polymorphonuclear neu-
trophils (PMN) in the presence of normal numbers of Lactobacillus
spp. (grade I-PMN) (Table 2).
Fig. 1. H2O2 production of vaginal bacteria of volunteer P1 as measured by direct inoculation of 75 ll of the vaginal E swab medium on TMBplus agar plates at each visit.
Table 1
Reported adverse events.
Adverse eventa All adverse events Possibly drug-related adverse events
Control group Lyophilized powder Starch pellets Control group Lyophilized powder Starch pellets
Pruritus vulvae 1 1
Leukorrhea 3 2 2 1
Vaginal discharge (Brownish) 1 1 1 1
Vaginal bleeding/spotting 1 1 1
Abdominal pain 1 1








Breast pain female 1
Erythema 1
Vaginal loss of ‘powder’ 2 2 2 2
a (1) Definitely not related, (2) probably not related, (3) possibly related, (4) probably related, (5) definitely related.
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Immediately, following the withdrawal bleeding, four volun-
teers had an abnormal microflora, whereby three, i.e. two with
grade II and with one grade III, belonged to the control group
and one, with grade I-like smear, was from group P. At day 35,
two volunteers from group P presented with abnormal microflora
while all other volunteers showed a normal microflora.
Although 11 of the 18 volunteers had PMN in the vaginal smear
on at least one study visit, high levels of PMN were observed only
in one woman at screening (Table 2). The number of women for
whom PMN were present in the vaginal smear was highest in the
control group at days 6 and 35.
While high levels of bare nuclei were not found in any of the
volunteers, a total of 13 of the 18 women had bare nuclei at least
one study day (Table 2). Respectively, three, three and two women
in groups C, L and P presented with bare nuclei at screening. The
number of women with bare nuclei was highest in group C (respec-
tively, three, four, one and one at day 6, 14, 22 and 35). Both in
group P and L, one or two women were found to have intermediate
or low levels of bare nuclei at all follow-up visits. All women with
bare nuclei had a grade I microflora, and the bare nuclei were pri-
marily present at a pH of 3.6, i.e. five of the nine women with bare
nuclei had a pH of 3.6 at screening, five of seven at day 6, all eight
women at day 14, two of the four at day 22 and none of the three at
day 35. Among the total of 49 remaining samples for which no bare
nuclei could be observed, pH values of 3.6 were observed only 15
times. Overall, there was a highly significant correlation
(p < 0.001) between vaginal pH and the presence of bare nuclei.
In particular, bare nuclei were associated with a lower median
pH of 3.6 (interquartile range 3.6–4.1) as compared to a median
pH of 4.1 (interquartile range 4.1–4.7) in samples not containing
bare nuclei, indicating a higher correspondence of vaginal mucosal
cytolysis with lower pH.
3.4. Hydrogen peroxide production
H2O2 production was assessed by culture of the vaginal swab on
TMBplus agar plates (Fig. 1). H2O2 production scores of the vaginal
microflora at day 35 were comparable with the scores at screening
(Fig. 2).
At screening, at day 6 and at day 14, all women, but one in the
control group, had a microflora comprising hydrogen peroxide-
producing lactobacilli based on color production on TMBplus agar
plates. Although immediately after the withdrawal bleeding at
day 22, there was a decrease in H2O2 scores in all but two women,
H202 production was restored in every single subject at midcycle,
even in the five women who completely lacked hydrogen perox-
ide-producing lactobacilli immediately after withdrawal bleeding.
4. Discussion
Among 18 volunteers who participated in this study, aimed at
comparing the effect of starch-based and lyophilized lactose/
skimmed milk carriers of probiotic formulations on the vaginal
pH and microflora and studying possible adverse effects and
events, we found that 16 out of 18 women showed the same cyclic
variation in pH and Gram stain. Although immediately after with-
drawal bleeding, 8 out of 18 women had either an elevated pH
(<4.7), a disturbed microflora or lacked hydrogen peroxide-produc-
ing lactobacilli, at midcycle all had hydrogen peroxide-producing
lactobacilli and a normal pH (pH between 3.6 and 4.7), and all
but two women from group P had a normal Gram stain.
Fig. 2. Mean pH (-) and H2O2 score (. . .) in control (j), starch-based pellets (N) and
lyophilized powder (o) groups.
Table 2
Gram staining, bare nuclei and pH results for the six subjects of each of the three groups.
Subjecta Screening Day 6 Day 14 Day 22 Day 35
Gradeb BNc pH Grade BN pH Grade BN pH Grade BN pH Grade BN pH
C1 Ia ! 4.1 Ia ++ 3.6 Ia ++ 3.6 Ia ! 3.6 Ia ! 4.0
C2 Ia + 4.1 Ia ! 3.6 Ia + 3.6 Ia + 3.6 Ia ! 4.1
C3 Ia + 3.6 Ia + 3.6 Ia + 3.6 Ia ! 3.6 Ia + 4.1
C4 Ib ! 4.1 Ia ! 4.1 Ia ! 4.1 II ! 6.1 Ia ! 4.1
C5 Iab ! >6.1 Ib ! 4.1 Ib ! 3.6 III ! 5.6 Ia ! 4.1
C6 Ia + 4.0 Ia + 3.6 Ia + 3.6 II ! >6.5 Ia ! 3.6
P1 Ib ! 4.7 Ib ! 4.7 Ib ! 4.1 I-like ! 6.1 I-like ! 4.1
P2 Ia + 3.6 Ia + 4.1 Ia + 3.6 Iab + 4.1 Ia ++ 4.1
P3 Ib ! 4.1 Ib ! 4.1 Ib ! 4.1 Ib + 4.7 Ib ! 4.1
P4 Ia ! 4.7 Ia ! 5.0 Ia ! 4.1 0 ! 5.8 Ia ! 4.4
P5 Ia ++ 3.6 Ia + 3.6 Ia ++ 3.6 Iab ! 4.7 Iab ! 3.6
P6 Ib ! >6.1 Ib ! 4.1 Ib ! 4.1 Ib ! 4.4 III ! 4.4
L1 Ib ! 4.1 Ib ! 3.6 Iab + 3.6 Iab + 3.6 Iab ! 3.6
L2 Ib + 4.7 Ib ! 4.1 Iab ! 4.1 Ia ! 4.4 Ib ! 5.0
L3 Ia-PMN ! 3.6 Ia + 4.1 Ia + 3.6 Ia ! 4.7 Ia ++ 4.4
L4 Ia + 4.1 Ia ! 4.0 Ia ! 3.6 Ia ! 5.6 Ia ! 4.7
L5 Ia + 3.6 Ia ! 3.6 Iab ! 3.6 Ia ! 3.6 Ia ! 4.4
L6 Ia + 3.6 Ia + 3.6 Ia ! 3.6 Ib ! 5.0 Iab ! 3.6
a C: control group: no administration, P: group with administration of starch pellets, L: group with administration of lyophilized powder.
b Gram stain scoring according to Claeys criteria [7,8].
c Presence of bare nuclei (BN): no bare nuclei: !, low quantity of bare nuclei (less than 10 per hpf): +, intermediate quantity of bare nuclei (between 10 and 50 per hpf): ++.
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The data show that, immediately after withdrawal bleeding, no
Gram stain-based changes in microflora could be observed in
group L, in contrast to the control group and group P, although
the drop in H2O2 production and the raise in pH were comparable
to both other groups. This observation tends to confirm the finding
that lyophilized skimmed milk and lactose, even when applied
vaginally on their own, can alter the vaginal microflora by stimu-
lating the growth of lactobacilli [12]. Because this study comprises
only 18 women randomized to three different groups, this observa-
tion lacks statistical power.
Although we found a high number of samples (31 out of 80)
with the presence of bare nuclei, this could not be related to the
administration of the formulations, since most women with bare
nuclei were observed in the control group. An abundant growth
of vaginal lactobacilli in combination with the presence of bare nu-
clei is known as cytolytic vaginosis [9,13,14]. The underlying
mechanisms remain elusive. The condition is characterized by a
very low pH (3.5–4.5) and this excessive acidity is thought to be
toxic for the vaginal environment thereby leading to cytolysis of
the vaginal epithelial cells [9,15,16]. Also, in this study, we found
a significant correlation between the presence of bare nuclei and
low pH, i.e. 20 of 31 vaginal samples with bare nuclei had a pH
of 3.6, compared to 15 of 49 vaginal samples without bare nuclei.
Consequently, on microscopic examination, lactobacilli are ob-
served along with fragmented or lysed epithelial cells with bare
nuclei and cellular debris. In this study, 26 of the 31 vaginal sam-
ples with bare nuclei were characterized by grade Ia microflora, 3
out of 31 and 2 out of 31 vaginal samples with bare nuclei were
characterized by grade Iab and grade Ib, respectively.
Vaginal symptoms in group P included cervical pain, brownish
vaginal discharge and spotting and were presumably procedure-
related following speculum examination. Also, brownish vaginal
discharge reported by women in group L was likely to be investiga-
tional procedure related and the only AEs that were considered as
possibly drug related were whitish discharge as this consistently
reflected loss of powder. Whereas both vaginal drug delivery forms
appear to be safe, it has be to be acknowledged that these vehicles
may cause some transient discomfort through increased vaginal
discharge as is also observed with established vaginal delivery
forms such as creams, gels and ovules and with vaginal Lactobacil-
lus capsules [17].
Various studies have been performed to assess the acceptability,
safety and effectiveness of vaginal Lactobacillus formulations [17–
22]. Although in general, there were no significant differences in
the severity, nature and frequency of adverse events between the
intervention and the placebo group, a phase I, placebo-controlled
trial for the prevention of recurrent urinary tract infection by the
use of L. crispatus CTV-05 suppositories suggested that vaginal
installation of these capsules can induce a mild inflammatory re-
sponse in the bladder or vaginal mucosa in some subjects without
causing prolonged urogenital infection [18]. In this study, using
colposcopy, neither inflammatory signs nor any mucosal lesions
were observed in the three study groups.
5. Conclusions
No adverse events other than loss of whitish discharge were
reported, and all major changes in the status of the microflora
and pH value occurred immediately after the withdrawal bleeding,
a period that is characterized by disturbance of the vaginal micro-
flora and a decrease in hydrogen peroxide-producing strains
[23,24]. As such, we can conclude that the changes were due to
withdrawal bleeding and were not related to treatment, indicating
that fast-disintegrating starch pellets and lyophilized lactose/
skimmed milk are acceptable carrier materials for the vaginal
delivery of probiotic strains or other drugs.
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